Stockscreener 앱 받기
76.26
0.00%
0.00
전일 마감가:
$76.26
열려 있는:
$77.66
하루 거래량:
7.39M
Relative Volume:
3.07
시가총액:
$14.70B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-31.64
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-1.28%
1개월 성능:
+0.75%
6개월 성능:
+61.91%
1년 성능:
+123.57%
1일 변동 폭
$75.85
$78.13
1주일 범위
$70.95
$79.88
52주 변동 폭
$28.32
$79.88
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
76.26 | 14.70B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio prices $550 million convertible notes at 0.75% interest rate By Investing.com - Investing.com Nigeria
Latham & Watkins Advises on BridgeBio Pharma’s US$550 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next - TechStock²
Lobbying Update: $60,000 of BRIDGEBIO PHARMA lobbying was just disclosed - Quiver Quantitative
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected - Intellectia AI
BridgeBio Pharma prices $550M convertible bond offering - MSN
BridgeBio Pharma Prices $550 Million Convertible Notes Offering - Intellectia AI
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BridgeBio Pharma prices $550 million convertible notes offering By Investing.com - Investing.com Canada
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033 - Nasdaq
BridgeBio Pharma, Inc. Announces Pricing of $550 Million Convertible Senior Notes to Enhance Capital Structure and Extend Debt Maturity - Quiver Quantitative
BridgeBio Prices Offering of $550 Million Convertible - GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownHere's What Happened - MarketBeat
BridgeBio’s US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO - Yahoo Finance
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress - Yahoo Finance
BridgeBio plans $550 million convertible notes offering to refinance debt By Investing.com - Investing.com Nigeria
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio Pharma, Inc. Announces Private Offering of $550 Million Convertible Senior Notes to Strengthen Balance Sheet and Extend Debt Maturity - Quiver Quantitative
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio continues long term debt management strategy and announces proposed offering of convertible senior notes - marketscreener.com
Ideas Watch: What is the PEG ratio of BridgeBio Pharma IncPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
BridgeBio Pharma (BBIO) Gets a Buy from Raymond James - The Globe and Mail
BridgeBio Pharma stock hits all-time high at 78.69 USD By Investing.com - Investing.com Nigeria
Aug Reactions: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Catalysts & Long-Term Growth Plans - baoquankhu1.vn
Will BridgeBio Pharma Inc stock deliver strong dividend growth2025 Sector Review & Breakout Confirmation Alerts - moha.gov.vn
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighShould You Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.69 USD - Investing.com India
Nisa Investment Advisors LLC Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio reports $362.4 million in 2025 Attruby revenue By Investing.com - Investing.com Nigeria
BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
BridgeBio Pharma CEO Kumar sells $6m in BBIO stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Kumar sells $6m in BBIO stock - Investing.com
BridgeBio Showcases Attruby Growth and Pipeline Progress - TipRanks
BridgeBio stock maintains Buy rating at TD Cowen on strong Attruby sales - Investing.com Canada
BridgeBio Pharma reports Attruby product revenue $146 mln in Q4 - marketscreener.com
BridgeBio Pharma Reports Attruby Product Revenue $146 Mln In Q4 - TradingView — Track All Markets
BridgeBio reports $362.4 million in 2025 Attruby revenue - Investing.com
BridgeBio (BBIO) Highlights Strategic Advancements at Healthcare Conference - GuruFocus
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th ... - Bluefield Daily Telegraph
New genetic treatments move closer for heart and rare childhood diseases - Stock Titan
Tema Etfs LLC Sells 27,026 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Sectors Review: Is BridgeBio Pharma Inc in a bullish channelM&A Rumor & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Wrap: What makes BridgeBio Pharma Inc stock attractive to growth fundsQuarterly Market Summary & Risk Managed Investment Signals - Bộ Nội Vụ
Will BridgeBio Pharma Inc. stock benefit from commodity prices2025 Dividend Review & Daily Profit Maximizing Tips - ulpravda.ru
What hedge fund activity signals for BridgeBio Pharma Inc. stockMarket Sentiment Report & Weekly Chart Analysis and Guides - Улправда
BridgeBio’s receives EU approval for its Transthyretin Amyloidosis treatment - MSN
Discipline and Rules-Based Execution in BBIO Response - Stock Traders Daily
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Jan 08 '26 |
Sale |
73.97 |
40,000 |
2,958,855 |
735,686 |
4.73%
0.92%
자본화:
|
볼륨(24시간):